G-CON Manufacturing and Ori Biotech Collaborate to Develop an Integrated Modular Manufacturing Platform for Cell and Gene Therapy Developers
The collaboration improves CGT manufacturing through a standardized, scalable platform
College Station, TX and Woodcliff Lake, New Jersey – November 17, 2020 – G-CON Manufacturing, Inc. (G-CON), a leader in prefabricated flexible cleanroom solutions, and Ori Biotech Ltd. (Ori), an innovator in cell and gene therapy (CGT) manufacturing, announced today their global collaboration to offer a predesigned platform for flexible manufacturing of cell therapies. The non-exclusive collaboration integrates Ori’s proprietary, flexible CGT manufacturing platform with the highly innovative prefabricated cleanroom that is the G-CON POD. The combination of the two technologies will provide standardized CGT manufacturing in a closed platform that can be seamlessly scaled for clinical through commercial scale manufacturing.
Ori’s ability to increase throughput, improve quality and decrease cost coupled with G-CON’s extensive experience in building cGMP manufacturing facilities for various modalities will combine to achieve the ultimate goal to help therapy developers bring lifesaving therapies to patients more quickly and cost effectively.
“G-CON is a leader in flexible cell and gene therapy manufacturing and, with this collaboration, Ori continues to partner with best-in-class, expert suppliers across the CGT ecosystem. This partnership will help enable our vision for a fully integrated, automated, closed system manufacturing platform supporting the cell and gene therapy industry,” said Farlan Veraitch, Co-Founder and CSO, Ori Biotech. “Innovation that reduces the significant size and cost of cell and gene therapy manufacturing facilities to enable scalable capacity, distributed manufacturing and marks another step toward enabling our partners to bring their life saving treatments to patients at scale.”
“A significant, upfront investment of $50M-$150M is often required to develop manufacturing capacity and building large bricks and mortar manufacturing facilities presents major challenges for CGT developers. An Ori powered G-CON POD can provide a flexible model with rapid scalability to manufacture thousands of doses of advanced therapies in a much smaller footprint, reducing the required facility investment by up to 75%” added Jason C. Foster, CEO, Ori Biotech.
”Ori is a pioneer in the cell therapy field with a truly disruptive technology in development,” said Peter Makowenskyj, Director of Sales Engineering for G-CON. “Enhancing automation and closing the process really eliminates a lot of the high cost elements and manual interventions currently required in making cell therapies. Our collaboration aligns well with Pharma 4.0 initiatives along with distributed manufacturing and will ultimately bring these treatments to patients more quickly and cost effectively.”
About G-CON Manufacturing
G-CON Manufacturing designs, builds and installs prefabricated G-CON POD® cleanrooms. G-CON’s POD portfolio provides cleanrooms in a number of dimensions for a variety of uses, from laboratory environments to personalized medicine and production process platforms. G-CON POD® cleanroom units surpass traditional cleanroom structures in scalability, mobility and the possibility of repurposing the PODs once the production process reaches its lifecycle end. For more information, please visit G-CON’s website at http://www.gconbio.com.
About Ori Biotech
Ori is a London and New Jersey based cell and gene therapy (CGT) manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardizes CGT manufacturing allowing therapeutics developers to further develop and bring their products to market at commercial scale. The promise of the full stack Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs by combining hardware, software and data services.
Ori was founded by Professor Chris Mason (AVRO) and Dr. Farlan Veraitch (UCL) and has brought together a seasoned Board and executive management team with over 100 years of pharmaceutical, CGT and venture building experience including CEO Jason C. Foster (Indivior), CBO Jason Jones (Miltenyi Biotec), VP Tom Heathman (HCATS) alongside expert advisers like Bruce Levine, Anthony Davies and Bob Preti.